Monday, October 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· December 4, 2025

DMG Blockchain Solutions Announces AI Strategy Update and November Preliminary Operational Results

View original at globenewswire.com
DMG Blockchain Solutions Announces AI Strategy Update and November Preliminary Operational Results VANCOUVER, British Columbia, Dec. 04, 2025 (GLOBE NEWSWIRE) -- DMG Blockchain Solutions Inc…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • DMG is committed to partnerships with Indigenous communities with which they are cultivating new relationships

    80% confidence
  • DMG sees a longer-term opportunity to develop a pan-Canadian approach to delivering sovereign AI

    80% confidence
  • Bitcoin mining will remain part of DMG's future as a foundational element of digital asset financial services strategy, though it will migrate from Christina Lake

    80% confidence
  • The best way to monetize Christina Lake asset is to work with partners to build it into a world-class 50-megawatt critical IT load liquid-cooled AI data center

    80% confidence
  • DMG is highly focused on maximizing its return to shareholders that can be unlocked by enabling Christina Lake as a solely dedicated AI data center

    80% confidence
  • DMG expects to close the Boardman, Oregon facility transaction in the coming weeks

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com